The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Mechanism of action of memantine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Memantine is an uncompetitive NMDA receptor antagonist and prevents damage to AD patients caused by NMDA receptor overactivation.434”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [434]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Chen, H., Pellegrini, J., Aggarwal, S., Lei, S., Warach, S., Jensen, F., & Lipton, S. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 629
The Yin and Yang of NMDA receptor signalling
Hardingham, G. E., & Bading, H. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)00040-1 · Cited by 620
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 436
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
Expression Mechanisms Underlying NMDA Receptor‐Dependent Long‐Term Potentiation
NICOLL, R. A., & MALENKA, R. C. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11320.x · Cited by 365
Homeostatic plasticity and NMDA receptor trafficking
Pérez-Otaño, I., & Ehlers, M. D. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.03.004 · Cited by 356
PHARMACOKINETICS AND ANALGESIC EFFECTS OF I.M. AND ORAL KETAMINE
GRANT, I. S., NIMMO, W. S., & CLEMENTS, J. A. (1981) · British Journal of Anaesthesia · doi:10.1093/bja/53.8.805 · Cited by 355
Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels
Bormann, J. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90385-3 · Cited by 351
Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies
Danysz, W., Parsons, C. G., Kornhuber, J., Schmidt, W. J., & Quack, G. (1997) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(96)00037-1 · Cited by 322
Parsons, C. G., Quack, G., Bresink, I., Baran, L., Przegalinski, E., Kostowski, W., Krzascik, P., Hartmann, S., & Danysz, W. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00092-k · Cited by 311
Dementia of Alzheimer’s disease and other neurodegenerative disorders—memantine, a new hope
Sonkusare, S. K., Kaul, C. L., & Ramarao, P. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.05.005 · Cited by 307
Chen, H. S., & Lipton, S. A. (1997) · The Journal of Physiology · doi:10.1113/jphysiol.1997.sp021909 · Cited by 282
Parsons, C. G., Gruner, R., Rozental, J., Millar, J., & Lodge, D. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90029-3 · Cited by 279
Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex
Kornhuber, J., Bormann, J., Retz, W., Hübers, M., & Riederer, P. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90384-1 · Cited by 253
Amantadine Inhibits NMDA Receptors by Accelerating Channel Closure during Channel Block
Blanpied, T. A., Clarke, R. J., & Johnson, J. W. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4262-04.2005 · Cited by 251
Self-citationTrapping Channel Block of NMDA-Activated Responses By Amantadine and Memantine
Blanpied, T. A., Boeckman, F. A., Aizenman, E., & Johnson, J. W. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.77.1.309 · Cited by 249
Self-citationKrystal, J. (1999) · Harvard Review of Psychiatry · doi:10.1093/hrp/7.3.125 · Cited by 232
Sasaki, Y. F., Rothe, T., Premkumar, L. S., Das, S., Cui, J., Talantova, M. V., Wong, H.-K., Gong, X., Chan, S. F., Zhang, D., et al. (2002) · Journal of Neurophysiology · doi:10.1152/jn.00531.2001 · Cited by 212
Aracava, Y., Pereira, E. F. R., Maelicke, A., & Albuquerque, E. X. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.077172 · Cited by 200
Rammes, G., Rupprecht, R., Ferrari, U., Zieglgänsberger, W., & Parsons, C. G. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01872-9 · Cited by 200
Lipton, S. A. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6s610 · Cited by 194
Different sensitivities of NMDA receptor channel subtypes to non-competitive antagonists
Yamakura, T., Mori, H., Masaki, H., Shimoji, K., & Mishina, M. (1993) · NeuroReport · doi:10.1097/00001756-199306000-00021 · Cited by 181
Open-Channel Blockers at the Human α4β2 Neuronal Nicotinic Acetylcholine Receptor
Buisson, B., & Bertrand, D. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.3.555 · Cited by 179
Kashiwagi, K., Masuko, T., Nguyen, C. D., Kuno, T., Tanaka, I., Igarashi, K., & Williams, K. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12116-5 · Cited by 166
Sharp, F. R., Tomitaka, M., Bernaudin, M., & Tomitaka, S. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01817-8 · Cited by 158
Kornhuber, J., & Quack, G. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11785-u · Cited by 156
Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Palmer, G. C. (2001) · Current Drug Targets · doi:10.2174/1389450013348335 · Cited by 145
Banerjee, P., Samoriski, G., & Gupta, S. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081976 · Cited by 134
Parsons, C. G., Danysz, W., Bartmann, A., Spielmanns, P., Frankiewicz, T., Hesselink, M. B., Eilbacher, B., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00161-0 · Cited by 133
Excitotoxicity, apoptosis and neuropsychiatric disorders
Olney, J. W. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00002-4 · Cited by 130
Bräu, M. E., Dreimann, M., Olschewski, A., et al. (2001) · Anesthesiology · doi:10.1097/00000542-200101000-00024 · Cited by 128
The role of neural activity in synaptic development and its implications for adult brain function.
Aamodt, S. M., & Constantine‐Paton, M. (1999) · PubMed · Cited by 120
Parsons, C. G., Panchenko, V. A., Pinchenko, V. O., Tsyndrenko, A. Y., & Krishtal, O. A. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01228.x · Cited by 114
Chen, H.-S. V., & Lipton, S. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085142 · Cited by 112
Clinical Pharmacokinetics of Non-Opiate Abused Drugs
Busto, U., Bendayan, R., & Sellers, E. M. (1989) · Clinical Pharmacokinetics · doi:10.2165/00003088-198916010-00001 · Cited by 111
Molecular Rearrangements of the Extracellular Vestibule in NMDAR Channels during Gating
Sobolevsky, A. I., Beck, C., & Wollmuth, L. P. (2002) · Neuron · doi:10.1016/s0896-6273(01)00560-8 · Cited by 111
Yuan, H., Erreger, K., Dravid, S. M., & Traynelis, S. F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414215200 · Cited by 107
Rogawski, M. A. (2000) · Amino Acids · doi:10.1007/s007260070042 · Cited by 103
Mealing, G. A. R., Lanthorn, T. H., Murray, C. L., Small, D. L., & Morley, P. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37943-1 · Cited by 103
Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells
Bresink, I., Benke, T. A., Collett, V. J., Seal, A., Parsons, C. G., Henley, J. M., & Collingridge, G. L. (1996) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1996.tb15971.x · Cited by 102
Determinants of trapping block of N‐methyl‐ d ‐aspartate receptor channels
Bolshakov, K. V., Гмиро, В. Е., Tikhonov, D. B., & Magazanik, L. G. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01956.x · Cited by 98
The N-methyl-D-aspartate antagonist memantine retards progression of Huntington’s disease
Beister, A., Kraus, P., Kuhn, W., Dose, M., Weindl, A., & Gerlach, M. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_14 · Cited by 98
Sobolevsky, A. I., Koshelev, S. G., & Khodorov, B. I. (1998) · The Journal of Physiology · doi:10.1111/j.1469-7793.1998.047bf.x · Cited by 89
Maskell, P., Spéder, P., Newberry, N. R., & Bermúdez, I. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705559 · Cited by 84
Persson, J., Hasselström, J., Maurset, A., Oye, I., Svensson, J. O., Almqvist, O., Scheinin, H., Gustafsson, L. L., & Almqvist, O. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100353 · Cited by 72
Ionotropic Glutamate Receptors as Therapeutic Targets
Jellinger, K. A. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00786.x · Cited by 67
Design of antagonists for NMDA and AMPA receptors
Bolshakov, K. V., Kim, K., Potapjeva, N. N., Гмиро, В. Е., Tikhonov, D. B., Usherwood, P. N. R., Mellor, I. R., & Magazanik, L. G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.02.007 · Cited by 63
Two Blocking Sites of Amino-Adamantane Derivatives in Open N-Methyl-d-Aspartate Channels
Sobolevsky, A. I., & Koshelev, S. G. (1998) · Biophysical Journal · doi:10.1016/s0006-3495(98)77844-0 · Cited by 60
Oliver, D., Ludwig, J., Reisinger, E., Zoellner, W., Ruppersberg, J. P., & Fakler, B. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.1.183 · Cited by 43
Mealing, G. A. R., Lanthorn, T. H., Small, D. L., Murray, R. J. S., Mattes, K. C., Comas, T., & Morley, P. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29614-2 · Cited by 38
Захарова, Е. С., Danysz, W., & Bespalov, A. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2067-4 · Cited by 35
On the paradox of ion channel blockade and its benefits in the treatment of Alzheimer disease
Schmitt, H. P. (2005) · Medical Hypotheses · doi:10.1016/j.mehy.2005.03.011 · Cited by 34
Channel gating of NMDA receptors
Qian, A., & Johnson, J. W. (2002) · Physiology & Behavior · doi:10.1016/s0031-9384(02)00906-x · Cited by 33
Self-citation
Cited by
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
The chemical biology of clinically tolerated NMDA receptor antagonists
Chen, H. V., & Lipton, S. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03991.x · Cited by 474
NMDA receptors in clinical neurology: excitatory times ahead
Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70165-0 · Cited by 415
Metadata
- Authors
- JOHNSON, J., & KOTERMANSKI, S.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2006-02
- Volume
- 6
- Issue
- 1
- Pages
- 61-67
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2009297217
- Cited by
- 502
- References
- 57
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.